CTOs on the Move

Innovate Biopharmaceuticals

www.innovatebiopharma.com

 
Innovate is a clinical stage biotechnology company developing novel medicines for gastroenterological disorders.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Innovate Biopharmaceuticals raised $21M on 01/30/2018

Similar Companies

Logical Therapeutics

Logical Therapeutics is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioMedix

Previously Mr. Lerner has served as Vice President of Engineering and Technology for both Image Sensing Systems, Inc. and Telex Communications, Inc.

Alexza Pharmaceuticals

Alexza Pharmaceuticals, located in Mountain View, CA, is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza`s products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

Xilio Therapeutics

Xilio is a Waltham, Massachusetts-based biopharmaceutical company focused on defeating cancer. The company`s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.

Korro Bio

Korro Bio is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and common diseases. The company`s proprietary and modular platform, OPERA™ (Oligonucleotide promoted editing of RNA), builds on a deep understanding of ADAR biology, and combines data-driven design, oligo discovery and chemistry with clinically validated delivery vehicles, to achieve highly selective RNA editing. This unique technology enables the development of RNA editing therapeutics that deliver the functional benefits of gene therapy with a reversible, transient, titratable and specific treatment regimen, offering the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is based in Cambridge, Mass.